Disruptive Pharma AB
5LH0
Company Profile
Business description
Disruptive Pharma AB is a Swedish pharmaceutical technology company engaged in developing and commercializing Formulite, a patented drug delivery platform based on mesoporous magnesium carbonate (MMC). The platform is designed to improve the solubility, oral bioavailability and other properties of pharmaceutical compounds. The company operates through contract development, strategic partnerships, and licensing arrangements with pharmaceutical and biotechnology companies to develop and commercialize drug products using Formulite technology.
Contact
Dag Hammarskjolds vag 54B
Uppsala Science Park
Uppsala751 83
SWET: +46 735685329
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Why don’t good returns guarantee a 5-star rating?
Amy Arnott explains how Morningstar’s stock ratings work.
stocks
Overvalued ASX share has overly ambitious profit target
We think the new profit target is aggressive and unlikely to be met.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,997.30 | 168.10 | -1.83% |
| CAC 40 | 8,216.78 | 135.22 | -1.62% |
| DAX 40 | 26,045.37 | 553.27 | -2.08% |
| Dow JONES (US) | 50,764.98 | 843.19 | -1.63% |
| FTSE 100 | 10,689.87 | 191.68 | -1.76% |
| HKSE | 23,508.17 | 245.67 | -1.03% |
| NASDAQ | 24,251.97 | 257.79 | -1.05% |
| Nikkei 225 | 58,860.43 | 801.59 | -1.34% |
| NZX 50 Index | 14,306.96 | 3.19 | 0.02% |
| S&P 500 | 7,328.45 | 88.14 | -1.19% |
| S&P/ASX 200 | 8,883.20 | 161.50 | -1.79% |
| SSE Composite Index | 3,584.58 | 17.99 | -0.50% |